NVP AEW 541

Drug Profile

NVP AEW 541

Alternative Names: AEW-541; NVP-AEW-541

Latest Information Update: 11 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Insulin-like growth factor I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 11 Aug 2011 No development reported - Phase-I for Haematological malignancies in USA (PO)
  • 11 Aug 2011 No development reported - Phase-I for Solid tumours in USA (PO)
  • 24 Oct 2008 Phase-I clinical trials in Haematological malignancies in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top